Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Launched by LABORATOIRES THEA · Dec 23, 2013
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed and dated informed consent
- • Male or female aged from ≥ 18 years old.
- • Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection.
- Exclusion Criteria:
- • Best far corrected visual acuity \< 1/10
- • Severe blepharitis
- • Severe Dry Eye
About Laboratoires Thea
Laboratoires Thea is a leading independent pharmaceutical company specializing in ophthalmology, dedicated to the research, development, and commercialization of innovative eye care solutions. With a commitment to improving patient outcomes, Thea focuses on addressing unmet medical needs through a robust pipeline of products, including prescription medications, over-the-counter treatments, and medical devices. The company leverages advanced research methodologies and collaborates with healthcare professionals to enhance the quality of eye care globally. With a strong presence in numerous countries, Laboratoires Thea emphasizes excellence in clinical trials, ensuring the highest standards of safety and efficacy in its offerings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials